Cariprazine (Major Depressive Disorder) Market Current Trends, Size, Share, Industry Analysis, Competitive Intelligence, Growth, Opportunities and Forecasts to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023. Cariprazine (RGH-188) is being developed as an adjunctive treatment to antidepressant therapy in patients with MDD who had an inadequate response to antidepressant therapy, and as of April 2014, two Phase III clinical trials were ongoing (Forest Laboratories, NCT01715805; Forest Laboratories, NCT01838876). In addition, cariprazine is being developed for the treatment of schizophrenia and bipolar disorder. Browse full report on: http://www.radiantinsights.com/research/cariprazine-majordepressive-disorder-forecast-and-market-analysis-to-2023 Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Cariprazine including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Cariprazine for the top eight countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of Cariprazine performance
- Obtain sales forecast for Cariprazine from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia). Table Of Content: 1 Table of Contents 5 1.1 List of Tables 8 1.2 List of Figures 8 2 Introduction 9 2.1 Catalyst 9 2.2 Related Reports 9 2.3 Upcoming Related Reports 11 3 Disease Overview 12 3.1 Etiology and Pathophysiology 12 3.1.1 Etiology 12 3.1.2 Pathophysiology 12 3.2 Classification 14 3.3 Symptoms and Subtypes of Major Depressive Disorder 16 3.4 Prognosis 17 3.5 Quality of Life 17 Request Free Sample Of This Study @ http://www.radiantinsights.com/research/cariprazine-major-depressive-disorder-forecastand-market-analysis-to-2023#tabs-4 4 Disease Management 18 4.1 Diagnosis and Treatment Overview 18 4.1.1 Diagnosis 18 4.1.2 Treatment Guidelines and Leading Prescribed Drugs 19 4.1.3 Clinical Practice 22 5 Competitive Assessment 27 5.1 Overview 27 6 Unmet Needs and Opportunities 29 6.1 Overview 29 6.2 More Effective Pharmacotherapies 30 6.2.1 Unmet Needs 30 6.2.2 Gap Analysis 31 6.2.3 Opportunities 32 6.3 More Favorable Side Effect Profiles 32 6.3.1 Unmet Needs 32 6.3.2 Gap Analysis 33
6.3.3 Opportunities 33 6.4 Rapid Onset of Antidepressant Effects 34 6.4.1 Unmet Needs 34 6.4.2 Gap Analysis 34 6.4.3 Opportunities 34 6.5 Personalized Treatment Approach 35 6.5.1 Unmet Needs 35 6.5.2 Gap Analysis 36 6.5.3 Opportunities 36 7 Pipeline Assessment 37 7.1 Overview 37 7.2 Promising Drugs in Clinical Development 37 8 Cariprazine (RGH-188) 40 8.1 Overview 40 8.2 Efficacy 42 8.3 Safety 42 8.4 Dosing and Formulation 43 8.5 Potential Clinical and Commercial Positioning 43 8.6 SWOT Analysis 44 8.7 Forecast 44 Browse All Reports of This Category @ http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare 9 Appendix 46 9.1 Bibliography 46 9.2 Abbreviations 50 9.3 Methodology 52 9.4 Forecasting Methodology 52 9.4.1 Diagnosed MDD Patients 52 9.4.2 Percent of Drug-Treated Patients 52 9.4.3 General Pricing Assumptions 53 9.4.4 Generic Erosion 54 9.4.5 Pricing of Pipeline Agents 54 9.5 Physicians and Specialists Included in this Study 55 9.6 About the Authors 57 9.6.1 Analyst 57 9.6.2 Therapy Area Directors 57 9.6.3 Global Head of Healthcare 58 9.7 About GlobalData 59 9.8 Disclaimer 59
About Us Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of Ancillary services such as, research partnerships/ tie-ups and customized research solutions. Media Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Website: Radiant Insights Visit Our Blog: radiantri.blogspot.com